From Wikipedia, the free encyclopedia
Demeclocycline
demeclocycline 2D skeletal
demeclocycline 3D BS
Clinical data
Trade namesDeclomycin
Other namesRP-10192, demethylchlortetracycline
AHFS/ Drugs.com Monograph
MedlinePlus a682103
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability60–80%
Protein binding41–50%
Metabolism Hepatic
Elimination half-life10–17 hours
Excretion Renal
Identifiers
  • (2E,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-1,2,3,4,4a,5,5a,6,12,12a-decahydrotetracene-1,3,12-trione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard ( EPA)
ECHA InfoCard 100.004.396 Edit this at Wikidata
Chemical and physical data
FormulaC21H21ClN2O8
Molar mass464.86 g·mol−1
3D model ( JSmol)
  • NC(=O)C1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@H]2C(C=1O)N(C)C
  • InChI=1S/C21H21ClN2O8/c1-24(2)14-7-5-6-10(16(27)12-9(25)4-3-8(22)11(12)15(6)26)18(29)21(7,32)19(30)13(17(14)28)20(23)31/h3-4,6-7,14-15,25-26,28-29,32H,5H2,1-2H3,(H2,23,31)/t6-,7-,14-,15-,21-/m0/s1 checkY
  • Key:FMTDIUIBLCQGJB-SEYHBJAFSA-N checkY
   (verify)

Demeclocycline ( INN, BAN, USAN, brand name Declomycin) is a tetracycline antibiotic which was derived from a mutant strain of Streptomyces aureofaciens. [1] [2]

Uses

Demeclocycline is officially indicated for the treatment of various types of bacterial infections. [3] It is used as an antibiotic in the treatment of Lyme disease, [4] acne, [5] and bronchitis. [6] Resistance, though, is gradually becoming more common, [7] and demeclocycline is now rarely used for treatment of infections. [8] [9]

It is widely used (though off-label in many countries including the United States) in the treatment of hyponatremia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) when fluid restriction alone has been ineffective. [10] Physiologically, this works by reducing the responsiveness of the collecting tubule cells to ADH. [11]

The use in SIADH actually relies on a side effect; demeclocycline induces nephrogenic diabetes insipidus (dehydration due to the inability to concentrate urine). [10] [12] [13]

The use of demeclocycline in SIADH was first reported in 1975, [14] and, in 1978, a larger study found it to be more effective and better tolerated than lithium carbonate, the only available treatment at the time. [15] Demeclocycline used to be the drug of choice for treating SIADH. [13] Meanwhile, it might be superseded, now that vasopressin receptor antagonists, such as tolvaptan, became available. [15]

Contraindications

Like other tetracyclines, demeclocycline is contraindicated in children and pregnant or nursing women. All members of this class interfere with bone development and may discolour teeth. [9]

Side effects and interactions

The side effects are similar to those of other tetracyclines. Skin reactions with sunlight have been reported. [15] Like only few other known tetracycline derivatives, demeclocycline causes nephrogenic diabetes insipidus. [16] Furthermore, demeclocycline might have psychotropic side effects similar to lithium. [17]

Tetracyclines bind to cations, such as calcium, iron (when given orally), and magnesium, rendering them insoluble and inadsorbable for the gastrointestinal tract. Demeclocycline should not be taken with food (particularly milk and other dairy products) or antacids. [9]

Mechanism of action

As with related tetracycline antibiotics, demeclocycline acts by binding to the 30S ribosomal subunit to inhibit binding of aminoacyl tRNA which impairs protein synthesis by bacteria. It is bacteriostatic (it impairs bacterial growth, but does not kill bacteria directly). [1] [7]

Demeclocycline inhibits the renal action of antidiuretic hormone by interfering with the intracellular second messenger cascade (specifically, inhibiting adenylyl cyclase activation) after the hormone binds to vasopressin V2 receptors in the kidney. [18] [19] [20] Exactly how demeclocycline does this has yet to be elucidated, however. [20]

Brand names

Brand names include Declomycin, Declostatin, Ledermycin, Bioterciclin, Deganol, Deteclo, Detravis, Meciclin, Mexocine, and Clortetrin.[ citation needed]

References

  1. ^ a b Chopra I, Hawkey PM, Hinton M (March 1992). "Tetracyclines, molecular and clinical aspects". The Journal of Antimicrobial Chemotherapy. 29 (3): 245–277. doi: 10.1093/jac/29.3.245. PMID  1592696.
  2. ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 356–. ISBN  978-1-4757-2085-3.
  3. ^ "Demeclocycline Hydrochloride - demeclocycline tablet". DailyMed. U.S. National Library of Medicine. Retrieved 2008-12-20.
  4. ^ Rosner B (2007). "The Antibiotic Rotational Protocol". The Top 10 Lyme Disease Treatments: Defeat Lyme Disease with the Best of Conventional and Alternative Medicine. BioMed Publishing. pp. 84, 86. ISBN  9780976379713.
  5. ^ "Ad Hoc Committee report: systemic antibiotics for treatment of acne vulgaris: efficacy and safety". Archives of Dermatology. 111 (12): 1630–1636. December 1975. doi: 10.1001/archderm.1975.01630240086015. PMID  128326.
  6. ^ Beatson JM, Marsh BT, Talbot DJ (1985). "A clinical comparison of pivmecillinam plus pivampicillin (Miraxid) and a triple tetracycline combination (Deteclo) in respiratory infections treated in general practice". The Journal of International Medical Research. 13 (4): 197–202. doi: 10.1177/030006058501300401. PMID  3930309. S2CID  23485353.
  7. ^ a b Schnappinger D, Hillen W (June 1996). "Tetracyclines: antibiotic action, uptake, and resistance mechanisms". Archives of Microbiology. 165 (6): 359–369. Bibcode: 1996ArMic.165..359S. doi: 10.1007/s002030050339. PMID  8661929. S2CID  6199423.
  8. ^ Klein NC, Cunha BA (July 1995). "Tetracyclines". The Medical Clinics of North America. 79 (4): 789–801. doi: 10.1016/S0025-7125(16)30039-6. PMID  7791423.
  9. ^ a b c Lexi-Comp (August 2008). "Demeclocycline". The Merck Manual Professional. Retrieved on October 27, 2008.
  10. ^ a b Goh KP (May 2004). "Management of hyponatremia". American Family Physician. 69 (10): 2387–2394. PMID  15168958. Archived from the original on 2008-10-16. Retrieved 2008-10-28.
  11. ^ Kortenoeven ML, Sinke AP, Hadrup N, Trimpert C, Wetzels JF, Fenton RA, Deen PM (December 2013). "Demeclocycline attenuates hyponatremia by reducing aquaporin-2 expression in the renal inner medulla". American Journal of Physiology. Renal Physiology. 305 (12): F1705–F1718. doi: 10.1152/ajprenal.00723.2012. PMID  24154696. S2CID  17815411.
  12. ^ Hayek A, Ramirez J (August 1974). "Demeclocycline-induced diabetes insipidus". JAMA. 229 (6): 676–677. doi: 10.1001/jama.1974.03230440034026. PMID  4277429.
  13. ^ a b Miell J, Dhanjal P, Jamookeeah C (December 2015). "Evidence for the use of demeclocycline in the treatment of hyponatraemia secondary to SIADH: a systematic review". International Journal of Clinical Practice. 69 (12): 1396–1417. doi: 10.1111/ijcp.12713. PMC  5042094. PMID  26289137.
  14. ^ Cherrill DA, Stote RM, Birge JR, Singer I (November 1975). "Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion". Annals of Internal Medicine. 83 (5): 654–656. doi: 10.7326/0003-4819-83-5-654. PMID  173218.
  15. ^ a b c Tolstoi LG (2002). "A brief review of drug-induced syndrome of inappropriate secretion of antidiuretic hormone". Medscape Pharmacotherapy. 4 (1). Archived from the original on June 6, 2013.
  16. ^ Cox M (1982). "Tetracycline Nephrotoxicity". In Porter GA (ed.). Nephrotoxic Mechanisms of Drugs and Environmental Toxins. Boston, MA: Springer. pp. 165–177. doi: 10.1007/978-1-4684-4214-4_15. ISBN  978-1-4684-4216-8.
  17. ^ Mørk A, Geisler A (January 1995). "A comparative study on the effects of tetracyclines and lithium on the cyclic AMP second messenger system in rat brain". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 19 (1): 157–169. doi: 10.1016/0278-5846(94)00112-U. PMID  7708928. S2CID  36219362.
  18. ^ Verbalis JG (2014). "Disorders of water metabolism". In Fliers E, Korbonits M, Romijn JA (eds.). Clinical Neuroendocrinology. Handbook of Clinical Neurology. Vol. 124. Elsevier Science. pp. 37–52 (43). doi: 10.1016/B978-0-444-59602-4.00003-4. ISBN  978-0-444-62612-7. PMID  25248578.
  19. ^ Kovács L, Lichardus B (6 December 2012). Vasopressin: Disturbed Secretion and Its Effects. Springer Science & Business Media. pp. 180–. ISBN  978-94-009-0449-1.
  20. ^ a b Singh AK, Williams GH (12 January 2009). Textbook of Nephro-Endocrinology. Academic Press. pp. 251–. ISBN  978-0-08-092046-7.
Retrieved from " https://en.wikipedia.org/?title=Demeclocycline&oldid=1206167424"